Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.
IPO Year:
Exchange: NASDAQ
Website: ensysce.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/30/2021 | $4.00 | Buy | Lake Street |
SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company's clinical advisory board.Dr. Osman, a highly versatile board-certified neurologist, migraine and pain specialist, has over ten years of experience in both R&D and
SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced that Lee Rauch has been appointed to the Company's board of directors. Ms. Rauch, an experienced Chief Executive Officer and Strategy Advisor, has served both public and private companies. During her near 40-year career, Ms. Rauch successful built companies ranging in focus from pre-clinical research to advanced clinical development, took
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. Dr. Pestano has worked through her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. Dr. Pestano received her PhD from Tuffs University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston. Her early research was vi
424B5 - Ensysce Biosciences, Inc. (0001716947) (Filer)
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
10-Q - Ensysce Biosciences, Inc. (0001716947) (Filer)
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
EFFECT - Ensysce Biosciences, Inc. (0001716947) (Filer)
POS AM - Ensysce Biosciences, Inc. (0001716947) (Filer)
EFFECT - Ensysce Biosciences, Inc. (0001716947) (Filer)
SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale of an aggregate of 3,553,194 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.47 per share (or common stock equivalent in lieu thereof) in a registered direct offering. The Company also entered into definitive agreemen
New York, NY, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ:ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks. The update note is available here. Ensysce August 2024 Note Highlights from the note include: NIH and NIDA Award $14 Million Grant to Ensysce Biosciences for Opioid Development with Overdose Protection: Ensysce Biosciences has received a $14 million grant from the National Institutes of Health (NIH) and the Natio
Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received Investigational Review Board ("IRB") approval of the PF614-MPAR-102 protocol, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 capsule is Co‑Administered with Nafamostat as a combination Immediate Release solution and Extended-Rel
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ:ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks. The update note is available here. Highlights from the note include: Pivotal Developments in Clinical Trials, Manufacturing Partnerships, and Regulatory Approvals in the First Half of 2024: Ensysce Biosciences, Inc. has made notable advancements in the first half of 2024. The company provided a comprehensive mid-year update, h
PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of OxycodoneOpioid Use Disorder Program Advances with Selection of PF9001 as Lead Drug Candidate PF614 Phase 3 Protocol Being Finalized for Submission to FDA SAN DIEGO, CA / ACCESSWIRE / August 14, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the second quarter ended June 30, 2024.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our FDA
~ PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company's symposium illustrated the current landscape of severe pain, including post-surgical and cancer pain treatment, and discussed potential innovative treatment options, noting the li
~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~ SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a Company review and update on a successful first half of 2024, including achievement of Breakthrough Therapy designation from the U.S. Food & Drug Administration (FDA).Recent clinical and development highlig
~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that the Company will host a symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain on August 8, 2024 in Amsterdam, Netherlands. The Symposium entitled: ‘Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen, Professor of A
~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~ SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides takeaways from Geoff Birkett, the Company's Chief Commercial Officer, following his participation on the opening panel of the European Pharmaceutical Market Research Association (EPHMRA) Annual Conference in London on June 25.Geoff Birkett discussed "The Future of Healthcare Research" with industry partners and underlined the import
~ Collaboration with Purisys Positions Ensysce to Expedite Lead OUD Candidate, PF9001, to IND Studies ~ SAN DIEGO, CA / ACCESSWIRE / June 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced an agreement with Purisys LLC ("Purisys") to scale the manufacture of the Company's lead opioid use disorder (OUD) drug candidate. PF9001, as recently announced, is a novel agent developed with Ensysce's unique TAAP technology to treat OUD that will potentially decrease the cardiovascular side effects associa
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday's after-market session. The market value of their outstanding shares is at $12.0 million. Dynatronics (NASDAQ:DYNT) stock rose 14.74% to $0.4. The company's market cap stands at $2.1 million. Oncology Institute (NASDAQ:TOI) shares moved upwards by 10.8% to $0.45. The market value of their outstanding shares is at $33.5 million. SAB Biotherapeutics (NASDAQ:SABS) stock rose 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million. Bone Biologics (NASDAQ:BBLG) shares moved upwards by 8.04% to $1.61. The company's market cap stands at $1.7 million. Virpax Pharmaceuticals (NASDAQ:VRPX) s
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice on May 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the equity requirement in Listing Rule 5550(b)(1), as described in the Hearing Panel's decision dated February 26, 2024, as amended. As a result, Ensysce common stock will continue trading on Nasdaq's Capital Market tier.
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 103.2% to $1.0 during Thursday's pre-market session. The company's market cap stands at $23.7 million. iSpecimen (NASDAQ:ISPC) stock moved upwards by 30.67% to $0.41. The market value of their outstanding shares is at $4.1 million. P3 Health Partners (NASDAQ:PIII) stock increased by 25.51% to $0.63. The company's market cap stands at $75.3 million. Bicycle Therapeutics (NASDAQ:BCYC) stock increased by 12.04% to $24.0. The company's market cap stands at $913.7 million. Calliditas Therapeutics (NASDAQ:CALT) stock moved upwards by 11.42% to $24.19. The market value of their outstanding shares is at $649.1 million. The company's, Q1 ea
New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.PF614-MPAR is the Company's Multi-Pill Abuse Protection (MPAR) unique combination opioid product which shuts off opioid release
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.90) by 38.89 percent. The company reported quarterly sales of $305.722 thousand which missed the analyst consensus estimate of $400.000 thousand by 23.57 percent. This is a 61.28 percent decrease over sales of $789.635 thousand the same period last year.
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.87) by 29.89 percent. This is a 93.8 percent increase over losses of $(18.24) per share from the same period last year. The company reported quarterly sales of $515.03 thousand which beat the analyst consensus estimate of $390.00 thousand by 32.06 percent. This is a 64.06 percent decrease over sales of $1.43 million the same period last year.
Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq"), as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).
SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13D/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13D/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13D/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
SC 13D - Ensysce Biosciences, Inc. (0001716947) (Subject)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are proud of the significant progress Ensysce has made in 2023 both operationally and clinically for our lead pain therapeutic, PF614, and our overdose protection product, PF614-MPAR.
~ Reminder: Corporate Update Conference Call to be Held Today at 11:00am ET ~SAN DIEGO, CA / ACCESSWIRE / April 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. As a reminder, the Company will be holding a corporate update conference call today, Tuesday, April 11, 2023, at 11:00am ET.Corporate Update Conference CallDate: Tuesday, April 11, 2023Time: 11:00am ETU.S. Dial-in: 1-877-407-0792International Dial-in: 1-201-689-8263Webcast: ENSC Corporate Upd
SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, excl
Corporate Update Call to be Held Wednesday, November 16, 2022SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today reported financial results for the third quarter of 2022.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We remain focused on progressing our clinical development plans for our programs and achieving each milestone we have identified. I could not be more pleased with the recently reported positive topline results from our human abuse potential (H
~ Announces Timing of Corporate Update Call ~SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, today announced positive topline results from a human abuse potential (HAP) study for PF614. PF614 is a new class of analgesia, a Trypsin Activated Abuse-Protected oxycodone product. Ensysce's TAAPTM technology is designed to be highly resistant to tampering and abuse as compared to traditional Abuse Deterrent Formulations (ADFs) of oxycodone. The product's abuse-deterrent characte
~ Call to be Held Today, August 17, 2022 at 11am ET ~SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today released an updated investor presentation to its investor relations website accessible via https://ir.ensysce.com/.The investor presentation has been updated to reflect the previously released data from the Part B, Bioequivalence (BE) arm of the PF614-102 study examining the Company's novel Trypsin-Activated Abuse-Protected (TAAP) opioid, PF614. The BE
Corporate Update Call to be Held Wednesday, August 17, 2022SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the second quarter 2022.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "With a recently completed $8 million financing, we are well positioned to advance our clinical trials. We also just announced that we achieved our stated milestone of positive bioequivalence (BE) study data from trial PF614
~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the data from the Part B, Bioequivalence (BE) arm of the PF614-102 study examining the Company's novel Trypsin-Activated Abuse-Protected (TAAP) Opioid, PF614.The BE study follows the successful completion of the multi-ascending twice-daily dosing study of PF614 and compared the
Corporate Update Call to be Held Tuesday, May 17, 2022SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reported financial results for the first quarter 2022.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "The first few months of 2022 are off to an exciting start, evident in the most recent clinical results from trials PF614-102 and PF614-MPAR-101. As we progress on our studies and clinical trials, we are closer to realizing our missi
~ Results confirmed the safety and longer-lasting profile of PF614 versus OxyContin and provides first human data showing the potential for overdose protection with MPAR~~ Announces corporate update call timing ~SAN DIEGO, CA / ACCESSWIRE / May 5, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today presented results from the clinical trials PF614-102 and PF614-MPAR-101 at the SMi Pain Therapeutics meeting in London, UK.PF614-102The multi-ascending dose study (MAD) study examined 3
Lake Street initiated coverage of Ensysce Biosciences with a rating of Buy and set a new price target of $4.00